Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Juli Busquets i Berta Laquente

Pancreatic Cáncer Cases Projected to Rise in Spain as Cyst Surveillance and Targeted Therapy Highlighted

November 19, 2026 Health Desk Health

Pancreatic cancer cases are expected to rise sharply in Spain over the next year, with an estimated 10,405 new cases projected for 2026.

This aggressive malignancy remains one of the most challenging tumors to diagnose and treat, frequently being detected at advanced stages.

  • The 2026 projections estimate 10,405 new pancreatic cancer cases in Spain, according to the Spanish Society of Medical Oncology (SEOM).
  • Specific screening is recommended for pancreatic cysts, particularly in individuals over the age of 70, as some lesions carry malignant potential.
  • A newly approved targeted therapy, Daraxonrasib, has demonstrated improved survival rates for patients with metastatic pancreatic adenocarcinoma.

The increasing prevalence of pancreatic cancer is a major public health concern, particularly as it often presents with highly non-specific symptoms, making early detection exceptionally difficult. This difficulty is compounded by the fact that many patients arrive at clinical settings with the disease already advanced.

Epidemiology and Risk Factors Driving Pancreatic Cancer Incidence

Data from the Spanish Society of Medical Oncology (SEOM) indicates that the number of new cases of pancreatic cancer is increasing annually, a trend that contradicts the declining incidence seen in some other cancers. The 2026 projections estimate 10,405 new diagnoses in Spain, with 5,258 cases identified in men and 5,147 in women, according to the SEOM’s report on cancer figures in 2026.

Mortality related to this tumor remains high. Pancreatic cancer ranks as the third leading cause of cancer death in Spain, trailing only lung and colorectal cancers.

Risk factor analysis highlights several modifiable behaviors linked to the development of the disease. The risk associated with smoking is particularly well-documented, with the risk doubling or tripling for smokers, according to the SEOM. Beyond tobacco, research also connects obesity, lack of exercise, high consumption of saturated fats, and low consumption of fruits and vegetables, to increased risk.

The Role of Pancreatic Cysts in Disease Vigilance

Beyond malignant tumors, pancreatic cysts introduce another layer of clinical complexity. These fluid-filled lesions are detected with greater frequency in patients over the age of 70. Specialists estimate that these cysts may be present in up to 15% of the older population, according to the Hospital of Bellvitge’s medical team.

The consensus among medical professionals is that the majority of these cysts are benign and will not progress into cancer. However, certain types possess the potential for malignant evolution, necessitating careful clinical monitoring.

Juli Busquets destacó la importancia de vigilar los quistes pancreáticos, lesiones que se detectan con mayor frecuencia a partir de los 70 años, lo que subraya la necesidad de una atención especializada en estos casos.

Metric 2024/2026 Data 2008-2012 Data
Five-Year Survival (Men) 10.3% 7.8%
Five-Year Survival (Women) 12.1% 10.7%
New Cases (Spain, 2026) 10,405 Not specified

Targeted Therapy Advances in Metastatic Pancreatic Cancer

Medical progress has recently shifted the treatment paradigm for advanced, metastatic pancreatic cancer. A major advance involves daraxonrasib, a targeted therapy approved in Europe for patients with metastatic pancreatic adenocarcinoma who have received at least one prior treatment, according to the SEOM.

The drug functions as an inhibitor of RAS proteins, which are implicated in the growth of tumors and are altered in over 90% of pancreatic adenocarcinomas. For decades, RAS was considered a “imposible de tratar con fármacos,” according to the SEOM. Daraxonrasib offers a novel strategy against this mutated pathway.

The efficacy of this treatment was demonstrated in the RASolute 302 clinical trial (a Phase III study published in The New England Journal of Medicine), according to Elperiodico. The study involved 500 patients with metastatic pancreatic adenocarcinoma. In the trial results, the median overall survival was 13.2 months for those receiving daraxonrasib, compared to 6.7 months for those receiving second-line chemotherapy. This represents a 60% reduction in the risk of death, according to the SEOM.

Specialized Infrastructure for Complex Pancreatic Lesions

The Hospital of Bellvitge has established a dedicated consultation for cystic pancreatic lesions to streamline monitoring and care. This specialization is necessary because while a cyst may be benign, identifying high-risk lesions requires advanced diagnostic tools and expert judgment.

The institution has earned recognition as a CSUR centro de referencia for the surgical treatment of resectabilidad límite pancreatic cancer, accredited by the Ministry of Health.

Juli Busquets explicó la necesidad de estos equipos especializados, afirmando: “Centralizar la experiencia es fundamental para mejorar los resultados”, una coordinación que, según Laquente, permite combinar mejor la cirugía, la oncología y otras especialidades, according to La Vanguardia.

Future Trajectory of Pancreatic Cancer Research

“En la enfermedad avanzada también estamos viviendo avances importantes.”

The figures come from an organization with a long institutional history. The Spanish Society of Medical Oncology (SEOM) began developing its own clinical practice guidelines in 2010, after Spanish oncologists called for documents tailored to the peculiarities of the Spanish healthcare system, and since 2014 these guidelines have been freely available online.

An independent appraisal published in 2023 reviewed 33 of the society’s cancer guidelines and rated 84.8% of them as high quality, with the highest scores for clarity of presentation.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: European Commission Approves Rasonque for Metastatic Pancreatic Cancer Treatment · SIOG 2026 Annual Conference in Valencia addresses geriatric oncology gaps

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • Seville Brotherhood Awards Dr. Pérez Bernal First Luisa Roldán Prize for Transplant Work
  • Apple AirPods Pro 3: 8-Stunden-ANC-Akku, Manueller EQ via iOS 27, Proprietärer Puls-Pfad

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service